Flyknit may be very well experiencing a renaissance. In the ‘00s, Nike was desperately trying to come up with an innovation that could do it all: cut weight, perfect fit, provide breathability and ...
Nike’s Mind franchise focuses on using pressure points to induce feelings of calm and focus before and after competition — and a new construction for the sneaker is about to go wide. The Nike Mind 002 ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new daily pill being developed by veterinary scientists could help ...
Camp4 Therapeutics reported FY25 GAAP EPS of -$2.65, missing expectations, but ended with a robust $109.5 million cash position. Liquidity was significantly strengthened by private placements, equity ...
While Fred Again..’s USB project is ever-expanding, the latest era of it, USB002, ended with Fred’s fourth show at Alexandra Palace last weekend. Now, Fred is putting a cap on the whole thing with a ...
Hello, and welcome to the Protara Therapeutics ASCO GU Update Call. [Operator Instructions] As a reminder, this conference call is being recorded. If you have any objections, please disconnect at this ...
A canine health startup called Loyal has now raised more than $250 million to develop drugs that could help dogs—and perhaps one day humans—live longer, healthier lives. The company on February 11 ...
VTx-002 is an experimental gene therapy for ALS that has FDA fast-track designation. It targets toxic TDP-43 protein aggregates, a key driver of ALS progression. The therapy is in a Phase 1/2 clinical ...
Five NBA championships. Two Olympic gold medals. An 18-time All-Star, with more than 33,000 points to his name (not to mention one 81-point game). Just about any professional basketball player in ...
Immusoft of CA Inc., a wholly owned subsidiary of Immusoft Corp., has announced that the FDA has granted orphan drug designation to ISP-002, the company’s investigational engineered B-cell therapy for ...
In a phase 2 trial, intravesical TARA-002 showed a 72% complete response rate at any time among patients with high-grade NMIBC naïve to BCG. The investigational intravesical cell therapy TARA-002 ...
In an exclusive interview with Hypebeast, the designer shares how she turned her hand to transforming her favorite rum bottle.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results